Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma

•Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer.•KRAS mutations are characteristic in patients with endometrial MLA.•We report two cases of KRAS-mutated endometrial MLA with excellent and durable responses to lenvatinib and pembrol...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology reports 2021-08, Vol.37, p.100844, Article 100844
Main Authors: Shen, Sherry, Rubinstein, Maria M., Park, Kay J., Konner, Jason A., Makker, Vicky
Format: Article
Language:English
Subjects:
Case Reports and Case Series
Endometrial
KRAS
Lenvatinib
Mesonephric
Mesonephric-like
Pembrolizumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer.•KRAS mutations are characteristic in patients with endometrial MLA.•We report two cases of KRAS-mutated endometrial MLA with excellent and durable responses to lenvatinib and pembrolizumab.•Tumors with KRAS mutations may be particularly sensitive to lenvatinib, but this warrants further study.
ISSN:2352-5789
2352-5789
DOI:10.1016/j.gore.2021.100844